Olaparib approved for 800 prostate and breast cancer patients in England
Olaparib (Lynparza), a targeted cancer drug, has been approved for hundreds of patients with certain breast cancers and prostate cancers in England.
Apr 11, 2023
0
61
Organic Chemical: olaparib
Medical news and research articles
Genome-wide CRISPR screens identify PARP inhibitor sensitivity and resistance in prostate cancer
Prostate cancer tumors harboring BRCA1/2 mutations are exceptionally sensitive to PARP inhibitors, while genomic alterations in other DNA damage response (DDR) genes are less responsive. To identify previously unknown genes ...
Apr 4, 2023
0
50
Ethnic diversity and disparities in access to genetic testing impact prostate cancer development and treatment
More than 1.4 million men were diagnosed with prostate cancer in 2020 globally, but the molecular characteristics of the disease remain unexplored for the majority of patients around the world. In the final days of the Movember ...
Nov 28, 2022
0
31
Localizing BRCA gene mutations to better treat ovarian cancer
Mutations of BRCA1 and BRCA2 genes, which are inherited by 1 in 400 and 1 in 800 people respectively, significantly increase the risk of certain cancers such as ovarian, breast, pancreatic and prostate cancer.
Nov 28, 2022
0
55
Olaparib and adavosertib work best when given sequentially for DNA-damage response mutations in advanced tumors
Patients with cancers that are driven by certain mutations occurring in response to DNA damage can be safely treated with two drugs, olaparib and adavosertib, if they are given in sequence rather than concurrently.
Oct 27, 2022
0
62
